Citalopram co-promotion agreement with Warner-Lambert will be terminated immediately, Forest announces May 12. Forest will pay Warner-Lambert $14 mil. to terminate the agreement and Warner-Lambert will be excluded from any profits recorded after April 30. Forest reported earlier in May that its sales force has been expanded from 850 to 1,425 representatives, resulting in a decrease of net income for the quarter ending March 31. Warner-Lambert's merger partner Pfizer markets the competing antidepressant Zoloft. The termination agreement contains provisions "limiting Warner-Lambert employees previously involved in marketing or selling Celexa from marketing or selling" Zoloft for a specified period of time, Forest said
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Companies in Europe cannot delay business decision making much longer to wait for more certainty on major US policy shifts on tariffs and pricing.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Following EU approval of the first disease-modifying treatment for Alzheimer’s disease, and with a second expected soon, the European Medicines Agency plans to update its guidance to support the design of state-of-the-art clinical trials for the disease and enhance drug development.
